

**From:** [CAB KYRIAKIDES ARCHIVES](#)  
**To:** [REDACTED] (HR); [REDACTED] (HR)  
**Subject:** FW: EFPIA COVID-19 Situational assessment to 19 February 2021  
**Date:** lundi 22 février 2021 10:49:50  
**Attachments:** [COVID-19 EFPIA&VE Situational Assessment 19 February 2021 Final.docx](#)  
[~WRD000.jpg](#)

---

**From:** [REDACTED]@efpia.eu>  
**Sent:** Friday, February 19, 2021 4:54 PM  
**To:** [REDACTED] (EMA) <[REDACTED]@ema.europa.eu>; [REDACTED] (EMA) <[REDACTED]@ema.europa.eu>  
**Cc:** [REDACTED]@ema.europa.eu>; [REDACTED] (EMA) <[REDACTED]@ema.europa.eu>; RYS Andrzej Jan (SANTE) <[REDACTED]@ec.europa.eu>; [REDACTED] <[REDACTED]@ec.europa.eu>; [REDACTED] <[REDACTED]@ec.europa.eu>; [REDACTED] <[REDACTED]@efpia.eu>; [REDACTED] <[REDACTED]@efpia.eu>; [REDACTED] <[REDACTED]@emea.europa.eu>; KYRIAKIDES Stella (CAB-KYRIAKIDES) <[REDACTED]>; BRETON Thierry (CAB-BRETON) <[REDACTED]>; LENARCIC Janez (CAB-LENARCIC) <[REDACTED]>; [REDACTED] (EMA) <[REDACTED]@ema.europa.eu>; [REDACTED] <[REDACTED]@merck.com>; [REDACTED] <[REDACTED]@astrazeneca.com>; [REDACTED] <[REDACTED]@pfizer.com>; [REDACTED] <[REDACTED]@vaccineseurope.eu>; [REDACTED] <[REDACTED]@gsk.com>; GALLINA Sandra (SANTE) <[REDACTED]>; [REDACTED] (CAB-KYRIAKIDES) <[REDACTED]@ec.europa.eu>; [REDACTED] <[REDACTED]@efpia.eu>; [REDACTED] <[REDACTED]@efpia.eu>; DELSAUX Pierre (SANTE) <[REDACTED]@ec.europa.eu>; [REDACTED] (CAB-BRETON) <[REDACTED]@ec.europa.eu>; SPANOU Despina (CAB-SCHINAS) <[REDACTED]@ec.europa.eu>  
**Subject:** EFPIA COVID-19 Situational assessment to 19 February 2021  
Dear [REDACTED], dear [REDACTED]

Please find attached a brief summary of the information collected from EFPIA and Vaccines Europe member companies on the supply of medicines to date. **New elements are highlighted in red for ease of reference.**

One potential shortage reported previously has now become actual in France following an increase of demand and the company continues to work to address the issue. Moreover other risks, including the issue of supply of materials entering into the production of biological products we highlighted last week, remain.

As I did over the past few weeks, I take the liberty to copy this mail to select Commissioners and Commission colleagues, considering the relevance of this content for their work.

Please do not hesitate to reach out should you have any questions.

Best wishes,

[REDACTED]  
[REDACTED]  
[REDACTED]

EFPIA - European Federation of Pharmaceutical Industries and Associations  
Leopold Plaza Building  
Rue du Trône 108  
B-1050 Bruxelles

[REDACTED]  
Tel: [+3226262555](tel:+3226262555) (Switchboard)  
Email: [REDACTED]@efpia.eu  
[www.efpia.eu](http://www.efpia.eu)



**For more information related to COVID-19 see:**  
<https://efpia.eu/news-events/the-efpia-view/statements-press-releases/european-pharmaceutical-industry-response-to-coronavirus/>

On Fri, 12 Feb 2021 at 11:38, [REDACTED]@efpia.eu>  
wrote:

Dear [REDACTED], dear [REDACTED],

Please find attached, the brief summary of the information we collected from EFPIA and Vaccines Europe member companies on the supply of medicines to date. New elements are highlighted in red for ease of reference.

You will see EFPIA and Vaccines Europe members increasingly report concerns surrounding the provision of disposable materials required for the production of biotechnological products (including vaccines), an issue already flagged in previous reports. While a few isolated companies had alerted EFPIA on this issue some weeks ago, an increasing number of EFPIA and Vaccines Europe members have confirmed or raised this issue and expressed rising concern. If not remedied it may put at risk the manufacturing of biological products for a variety of health conditions, incl. life threatening ones (e.g. cancer), and vaccines in the medium term. We fear the situation will worsen as the production of C-19 vaccines will be scaled up. More details are provided in the attachment.

As in the past, as we consider that the contents of the attached briefing is highly relevant to the Commission's work, I hope you won't mind if I took the initiative to copy this mail to the Commissioners and to Commission colleagues.

Please do not hesitate to reach out if you have any questions.

Best wishes,

[REDACTED]  
[REDACTED]  
[REDACTED]

EFPIA - European Federation of Pharmaceutical Industries and Associations

Leopold Plaza Building  
Rue du Trône 108  
B-1050 Bruxelles

Tel: [REDACTED]  
Tel: +3226262555 (Switchboard)  
Email: [REDACTED]@efpia.eu  
[www.efpia.eu](http://www.efpia.eu)



**For more information related to COVID-19 see:**  
<https://efpia.eu/news-events/the-efpia-view/statements-press-releases/european-pharmaceutical-industry-response-to-coronavirus/>

On Fri, 5 Feb 2021 at 11:54, [REDACTED]@efpia.eu>  
wrote:

Dear [REDACTED], dear [REDACTED]

Pleas find attached, the brief summary of the information we collected from EFPIA and Vaccines Europe member companies on the supply of medicines to date. New elements are highlighted in red for ease of reference.

As in the past, as we consider that the contents of the attached briefing is highly relevant to the Commission's work, I hope you won't mind if I took the initiative to copy this mail to the Commissioners and to DG SANTE colleagues.

Please do not hesitate to reach out if you have any questions.

Best wishes,

[REDACTED]  
[REDACTED]  
[REDACTED]

EFPIA - European Federation of Pharmaceutical Industries and Associations  
Leopold Plaza Building  
Rue du Trône 108  
B-1050 Bruxelles

Tel: [REDACTED] (Direct Line)  
Tel: +3226262555 (Switchboard)  
Email: [REDACTED]@efpia.eu  
[www.efpia.eu](http://www.efpia.eu)



**For more information related to COVID-19 see:**  
<https://efpia.eu/news-events/the-efpia-view/statements-press-releases/european-pharmaceutical-industry-response-to-coronavirus/>

On Fri, 29 Jan 2021 at 15:29, [REDACTED]@efpia.eu>

wrote:

Dear [REDACTED], dear [REDACTED]

Following your email of 25 January, please find attached, the brief summary of the information we collected from EFPIA and Vaccines Europe member companies on the supply of medicines.

As in the past, as we consider that the contents of the attached briefing is highly relevant to the Commission's work, I hope you won't mind if I took the initiative to copy this mail to the Commissioners and to DG SANTE colleagues.

Please do not hesitate to reach out if you have any questions.

Best wishes,

[REDACTED]  
[REDACTED]  
[REDACTED]

EFPIA - European Federation of Pharmaceutical Industries and Associations  
Leopold Plaza Building  
Rue du Trône 108  
B-1050 Bruxelles

Tel: [REDACTED] (Direct Line)

Tel: [+3226262555](tel:+3226262555) (Switchboard)

Email: [REDACTED]@efpia.eu

[www.efpia.eu](http://www.efpia.eu)



**For more information related to COVID-19 see:**  
<https://efpia.eu/news-events/the-efpia-view/statements-press-releases/european-pharmaceutical-industry-response-to-coronavirus/>